MigVax, an affiliate of The Migal Galilee Research Institute, is a startup that developed Migvax-101, a novel oral subunit COVID-19 vaccine.

MigVax has developed a vaccine against avian Coronavirus and Infectious Bronchitis Virus (IBV) which can be administered orally. The COVID-19 vaccine project was initiated given the high similarity COVID-19 has with IBV and avian Coronavirus and are working towards genetic adjustments to develop an effective vaccine towards COVID-19. Oral administration increases safety, efficiency and are cost-effective in large scale manufacturing.